MarketInOut Stock Screener Log In | Sign Up
 

Zai Lab Ltd ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026 16:00
Zai Lab Ltd ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,474.35 mln
Float105 mln
Earnings Date11/05/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-2.72
Likely reliable

Relative Strength

40 / 100
Slightly lagging

Debt / Equity

0.42
Low leverage

Pre-Tax Margin

-42%
Deeply loss-making

ROE

-26.68
Deeply negative

Business Description

Zai Lab is a China-based biopharmaceutical company founded in 2013 that researches, develops, and sells treatments for cancer, immune disorders, neurological conditions, and infectious diseases. The company markets several approved drugs targeting conditions such as ovarian cancer, lung cancer, pneumonia, and rare neuromuscular diseases. Zai Lab works alongside a number of global pharmaceutical partners, including Pfizer, argenx, and Deciphera, to bring licensed treatments to patients.

Key Fundamentals

EPS-1.70
ROE-26.68
RPS4.06
ROIC-68.13
ROA-16.65
Interest Cover-44.13
EBITDA, mln-162
EV / EBITDA-15.39
EV / EBIT-13.49
Revenue, mln451
EV / Revenue5.54

Quote Details

Last 24.03
Change 1.99 (9.03%)
Open 23.19
Volume 3,689,403
Turnover 88,656,360
Average Volume 936,277

Financial Ratios

Pre-Tax Profit Margin-42
Leverage Ratio1.77
Current Ratio2.13
Price / Book4.87
Price / Tangible Book5.68
Debt / Equity0.42
Price / Sales6.49

Financial Strength

Altman Z-Score0.59
Piotroski F-Score 3 / 9
Beneish M-Score-2.72
Short Ratio8.38
Short % of Float6.50

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.62% 85 / 100   
1 Month -4.94% 40 / 100   
2 Months 17.11% 91 / 100   
6 Months 5.53% 74 / 100   
1 Year -17.39% 31 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog